On December 4, 2023, Nanobiotix S.A. closed the transaction. The company issued 901,256 additional ordinary shares of the Company, in the form of restricted American Depositary Shares at a price $5.36 for a gross proceeds $4,830,732.16 in its second and final tranche, the company has issued total 4,664,179 shares for total gross proceeds of $24,999,999.44 in the transaction.
Market Closed -
Other stock markets
|
After market 18:22:14 | |||
6.37 EUR | +2.58% | 6.368 | -0.03% |
04-25 | Transcript : Nanobiotix S.A., Q4 2023 Earnings Call, Apr 25, 2024 | |
04-24 | Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.07% | 315M | |
+18.19% | 47.02B | |
+48.77% | 41.86B | |
+0.48% | 41.76B | |
-4.27% | 28.8B | |
+11.80% | 26.05B | |
-22.10% | 19.15B | |
+4.43% | 12.55B | |
+29.48% | 12.34B | |
-3.93% | 11.82B |
- Stock Market
- Equities
- NANO Stock
- News Nanobiotix
- Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.